Company profile: GeneInsight
1.1 - Company Overview
Company description
- Provider of an IT platform that streamlines data interpretation and management; GeneInsight Suite has been in clinical use and evolving since 2005, developed at Partners HealthCare in collaboration with leading geneticists, laboratory operations personnel, practicing physicians, and IT professionals.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GeneInsight
Maze Therapeutics
HQ: United States
Website
- Description: Provider of precision medicines for renal, cardiovascular, and metabolic diseases, including MZE829, an oral candidate for APOL1 kidney disease that mimics protective genetic variants, and MZE001, an oral substrate reduction therapy for Pompe disease. Offers the Compass platform integrating variant functionalization into drug development and genetic medicine programs for chronic kidney and cardio-metabolic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Maze Therapeutics company profile →
MultiVir
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies, including investigational Ad-p53 and Ad-IL24 tumor suppressor immune gene therapies delivering normal genes into tumors to restore suppressor functions and stimulate anti-tumor responses; an Ad-p53 dendritic cell therapeutic vaccine; and combination regimens with anti-PD-1/PD-L1 for recurrent/metastatic cancers and advanced melanoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MultiVir company profile →
Day Zero Diagnostics
HQ: United States
Website
- Description: Provider of whole-genome sequencing–based tools and services for clinical pathogen detection, antimicrobial resistance profiling, and outbreak management, including Blood2Bac to enrich bacterial DNA directly from blood; Keynome ID for species identification; Keynome gAST for resistance profiling; MicrohmDB to support machine learning; and epiXact for pathogen relatedness insights for infection control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Day Zero Diagnostics company profile →
Oxford BioDynamics
HQ: United Kingdom
Website
- Description: Provider of epigenetic biomarker research and development solutions for pharma and biotech via its proprietary EpiSwitch platform, offering blood tests such as EpiSwitch PSE for prostate cancer risk, CiRT for checkpoint inhibitor therapy success, and CST for COVID-19 severity, plus genome mapping tools including EpiSwitch Platform, Explorer Array Kit, and EpiSwitch Portal for diagnostics, prognostics, and health outcome insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford BioDynamics company profile →
Astute Medical
HQ: United States
Website
- Description: Provider of diagnostic solutions for high-risk medical conditions via identification and validation of protein biomarkers, focused on community and hospital-acquired acute conditions needing rapid diagnosis and risk assessment. Products include BIOFIRE FILMARRAY Torch, VITEK MS, VIDAS BRAHMS PCT, and BACT/ALERT VIRTUO.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Astute Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GeneInsight
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GeneInsight
2.2 - Growth funds investing in similar companies to GeneInsight
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GeneInsight
4.2 - Public trading comparable groups for GeneInsight
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →